In accordance with the results of the Adverse Drug Reaction Evaluation, in order to further ensure the safety of public medication, on November 8, 2019, NMPA issued an Announcement with decisions made to revise the Entries of [warnings], [adverse reactions], [contraindications] and [precautions] of oral preparations (tablets, powders, soft capsules, capsules) such as Huoxuezhitong capsules.